Toremifene Citrate

Toremifene Citrate

Synonyms: FC 1157a; Fareston; NK 622; NSC 613680
CAS: 89778-27-8
Molecular Formula:  C26H28ClNO·C6H8O7
Molecular Weight: 598.09
Molecular Structure:
 
Melting Point:  158-164 ºC
Boiling Point:  535.1 ºC at 760 mmHg
Density: 1.045g/cm3 
Refractive index: 1,416-1,418
Appearance: White or almost white powder
1.background
Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.
In 2007 the pharmaceutical company GTx, Inc was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008[2]
An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009,[3] and in Oct 2009 the FDA said they would need more clinical data, e.g. another phase III trial

MORE INFORMATION PLS CONTACT
[email protected]
tel:86-027-50756155
shype:[email protected]